10 February 2006
Final approval process for MED2002
Futura Medical plc (AIM: FUM), the pharmaceutical drug and medical device group that develops innovative products for the sexual healthcare market, announces that the negotiated commercial terms and clinical development program for MED2002 are now going through the formal approval process within the major global pharmaceutical group (MGPG). This process will complete after the expiry of the current exclusivity period.
Futura has agreed to extend the exclusivity period to allow the MGPG to complete its decision-making process in the near term.
James Barder, Futura's Chief Executive, said: "I am delighted to report that we are now in the formal approval process within the global pharmaceutical group and I look forward to updating shareholders in due course."